Gene therapy compositions and methods for treating diseases of the retina
Patent Information
- Application Number
- HK62026125154
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-17
- Filing Date
- 2026-06-23
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
This invention provides recombinant AAV particles containing opsin transgenes for the treatment of retinal diseases, as well as related compositions and methods. Abstract
Claims
CLAIMSWhat is claimed is:
1. An infectious recombinant adeno-associated virus (rAAV) particle comprising (i) a capsid protein having a modified amino acid sequence relative to a native AAV capsid of serotype 2 and (ii) a vector genome consisting of a heterologous polynucleotide comprising from 5' to 3' (a) an AAV2 inverted terminal repeat sequence (ITR1); (b) a promoter sequence; (c) a polynucleotide sequence encoding a channelrhodopsin; (d) a polyadenylation sequence; and (e) an AAV2 inverted terminal repeat sequence (ITR2), wherein the heterologous polynucleotide does not encode a fluorescent protein.
2. The rAAV particle of claim 1, wherein the heterologous polynucleotide further comprises a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) between the polyadenylation sequence and the ITR2 sequence.
3. The rAAV particle of claim 2, wherein the WPRE element comprises SEQ ID NO: 14.
4. The rAAV particle of any one of claims 1 to 3, wherein the promoter is selected from a cytomegalovirus (CMV) promoter, an elongation factor la (EFla) promoter, a simian virus 40 (SV40) promoter, a chicken beta-actin promoter, an mGluR6 promoter, and a CAG promoter.
5. The rAAV particle of claim 4, wherein the promoter is a CAG promoter.
6. The rAAV particle of claim 5, wherein the CAG promoter comprises SEQ ID NO: 10.
7. The rAAV particle of claim 4, wherein the promoter is an mGluR6 promoter.
8. The rAAV particle of claim 7, wherein the mGluR6 promoter comprises SEQ ID NO: 24.
9. The rAAV particle of any one of claims 1 to 8, wherein the heterologous polynucleotide further comprises an enhancer sequence.
10. The rAAV particle of claim 9, wherein the enhancer is a CMV enhancer or an mGluR6 enhancer.
11. The rAAV particle of claim 10, wherein the enhancer is an mGluR6 enhancer comprising SEQ ID NO: 25.
12. The rAAV particle of any one of claims 1 to 11, wherein the promoter comprises an mGluR6 promoter comprising from upstream to downstream: intron 4 of the mGluR6 gene, intron 3 of the mGluR6 gene, an mGluR6 enhancer, and a fragment of the mGluR6 promoter.
13. The rAAV particle of claim 12, wherein the mGluR6 promoter comprises the nucleotide sequence of SEQ ID NO: 28.
14. The rAAV particle of any one of claims 1 to 13, wherein the channelrhodopsin comprises the amino acid sequence of ChRown (SEQ ID NO: 5).
15. The rAAV particle of any one of claims 1 to 14, wherein the channelrhodopsin comprises the amino acid sequence of ChRown (SEQ ID NO: 5), or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% identical thereto.
16. The rAAV particle of any one of claims 1 to 15, wherein the polyadenylation signal is a human growth hormone polyadenylation sequence (hGHpA) or a Simian virus 40 polyadenylation sequence.
17. The rAAV particle of claim 16, wherein the polyadenylation signal is a human growth hormone polyadenylation sequence (hGHpA) comprising SEQ ID NO: 18.
18. The rAAV particle of claim 1, wherein the heterologous polynucleotide comprises pCAG- Chrown-mWPRE-hGHpA (SEQ ID NO: 21) or pCAG-Chrown-hGHpA (SEQ ID NO: 23).
19. The rAAV particle of any one of claims 1 to 18, wherein the capsid protein comprises the amino acid sequence of SEQ ID NO: 7.
20. The rAAV particle of claim 19, wherein the capsid protein further comprises a substitution from tyrosine to phenylalanine at a position corresponding to position 444 of a wild-type AAV2 VP1 capsid sequence.
21. A pharmaceutical composition comprising a plurality of the rAAV particles of any one of claims 1 to 20, and a pharmaceutically acceptable carrier or excipient.
22. The pharmaceutical composition of claim 21, wherein the composition is formulated for intravitreal injection.
23. The pharmaceutical composition of claim 21 or 22, wherein the composition is formulated as an emulsion or suspension.
24. A method for treating a retinal disease in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount a pharmaceutical composition comprising a plurality of the rAAV particles of any one of claims 1 to 20 or the pharmaceutical composition of any one of claims 21 to 23, and optionally a pharmaceutically acceptable carrier or excipient.
25. The method of claim 24, wherein the rAAV particles are administered by intravitreal injection.
26. The method of claim 24 or 25, wherein the rAAV particles are administered in one or more doses.
27. The method of claim 26, wherein the one or more doses comprises at least about 1.5 x 108viral genomes (vg).
28. The method of claim 26, wherein the one or more doses comprises about 1 x 108to 1 x 1014viral genomes (vg).
29. The method of any one of claims 24 to 28, wherein the rAAV particles are administered in one or more doses per eye.
30. The method of any one of claims 24 to 29, wherein the retinal disease is selected from Bardet-Biedl syndrome, chorioretinal atrophy or degeneration, cone or cone-rod dystrophy, congenital stationary night blindness, Leber congenital amaurosis (LCA), macular degeneration (MD), including age-related MD (AMD), ocular-retinal developmental disease, optic atrophy, retinitis pigmentosa, syndromic / systemic diseases with retinopathy, Usher syndrome, or other retinopathy, including diabetic retinopathy.
31. The method of claim 30, wherein the retinal disease is age-related macular degeneration (AMD) or retinitis pigmentosa (RP).
32. A method of delivering a heterologous nucleic acid to a retinal cell comprising contacting the retinal cell with a plurality of the rAAV particles of any one of the preceding claims.
33. An infectious recombinant adeno-associated virus (rAAV) particle comprising (i) a capsid protein and (ii) a vector genome comprising a polynucleotide sequence encoding a channelrhodopsin, wherein: a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is positioned downstream of the polynucleotide sequence encoding the channelrhodopsin; the vector genome does not encode a fluorescent protein; or the capsid protein is an AAV2 7m8 serotype.
34. The rAAV particle of claim 33, wherein the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is positioned downstream of the polynucleotide sequence encoding the channelrhodopsin.
35. The rAAV particle of claim 33 or 34, wherein the WPRE element comprises SEQ ID NO: 14 or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.
36. The rAAV particle of any one of claims 33 to 35, wherein the vector genome does not encode a fluorescent protein.
37. The rAAV particle of any one of claims 33 to 36, wherein the capsid protein is an AAV2 7m8 serotype.
38. The rAAV particle of any one of claims 33 to 37, wherein the capsid protein comprises the amino acid sequence of SEQ ID NO: 7.
39. The rAAV particle of any one of claims 33 to 37, wherein the capsid protein or consists of the amino acid sequence of SEQ ID NO: 38.
40. The rAAV particle of any one of claims 33 to 37, wherein the capsid protein further comprises a phenylalanine at a position corresponding to position 444 of a wild-type AAV2 VP1 capsid sequence.
41. The rAAV particle of any one of claims 33 to 40, wherein the polynucleotide encoding the channelrhodopsin encodes the channel rhodopsin of SEQ ID NO: 5.
42. The rAAV particle of any one of claims 33 to 41, wherein the polynucleotide encoding the channelrhodopsin encodes an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 5.
43. The rAAV particle of claim 41 or 42, wherein the polynucleotide encoding the channelrhodopsin comprises SEQ ID NO: 17.
44. The rAAV particle of any one of claims 33 to 43, wherein the vector further comprises an upstream inverted terminal repeat (ITR), wherein the upstream ITR comprises SEQ ID NO: 15.
45. The rAAV particle of any one of claims 33 to 44, wherein the vector further comprises a downstream ITR, wherein the downstream ITR comprises SEQ ID NO: 16.
46. The rAAV particle of any one of claims 33 to 45, wherein the vector further comprises a polyadenylation sequence.
47. The rAAV particle of any one of claims 33 to 46, wherein the polyadenylation sequence is a human growth hormone polyadenylation sequence (hGHpA) or a Simian virus 40 polyadenylation sequence.
48. The rAAV particle of claim 46 or 47, wherein the polyadenylation sequence comprises SEQ ID NO: 18.
49. The rAAV particle of any one of claims 33 to 48, wherein the vector further comprises a promoter.
50. The rAAV particle of claim 49, wherein the promoter comprises a cytomegalovirus (CMV) promoter, an elongation factor la (EFla) promoter, a simian virus 40 (SV40) promoter, a chicken beta-actin promoter, an mGluR6 promoter, or a CAG promoter.
51. The rAAV particle of claim 49 or 50, wherein the promoter comprises SEQ ID NO: 10.
52. The rAAV particle of any one of claims 33 to 51, wherein the vector comprises SEQ ID NO: 34.
53. The rAAV particle of any one of claims 33 to 52, wherein the vector comprises SEQ ID NO: 29.
54. The rAAV particle of claim 49 or 50, wherein the vector comprises an mGluR6 regulatory element region, wherein the mGluR6 regulatory element region comprises the promoter.
55. The rAAV particle of claim 54, wherein the mGluR6 regulatory element comprises at least one of, at least two of, at least three of, or all four of SEQ ID NOS: 24-27.
56. The rAAV particle of claim 54 or 55, wherein the mGluR6 regulatory element comprises, from upstream to downstream: intron 4 of the mGluR6 gene, intron 3 of the mGluR6 gene, an mGluR6 enhancer, and a fragment of the mGluR6 promoter.
57. The rAAV particle of claim 55, wherein the mGluR6 regulatory element comprises SEQ ID NO: 28.
58. The rAAV particle of any one of claims 33-49 or 54-57, wherein the vector comprises SEQ ID NO: 30.
59. The rAAV particle of any one of claims 33-49 or 54-58, wherein the vector comprises SEQ ID NO: 31.
60. The rAAV particle of any one of claims 33 to 59, wherein the vector comprises, from upstream to downstream, (a) an AAV2 inverted terminal repeat sequence (ITR1); (b) a promoter sequence; (c) a polynucleotide sequence encoding the channelrhodopsin; (d) a polyadenylation sequence; and (e) an AAV2 inverted terminal repeat sequence (ITR2).
61. The rAAV particle of claim 60, wherein the vector comprises a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) positioned between the polyadenylation sequence and the ITR2 sequence.
62. A pharmaceutical composition comprising a plurality of the rAAV particles of any one of claims 33 to 61, and a pharmaceutically acceptable carrier or excipient.
63. The pharmaceutical composition of claim 62, wherein the composition is formulated for intravitreal injection.
64. The pharmaceutical composition of claim 62 or 63, wherein the composition is formulated as an emulsion or suspension.
65. A method for treating a retinal disease in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount a pharmaceutical composition comprising a plurality of the rAAV particles of any one of claims 33 to 61 or the pharmaceutical composition of any one of claims 62 to 64, and optionally a pharmaceutically acceptable carrier or excipient.
66. The method of claim 65, wherein the rAAV particles are administered by intravitreal injection.
67. The method of claim 65 or 66, wherein the rAAV particles are administered in one or more doses.
68. The method of claim 67, wherein the one or more doses comprises at least about 1.5 x 108viral genomes (vg).
69. The method of claim 67, wherein the one or more doses comprises about 1 x 108to 1 x 1014viral genomes (vg).
70. The method of any one of claims 65 to 69, wherein the rAAV particles are administered in one or more doses per eye.
71. The method of any one of claims 65 to 70, wherein the retinal disease is selected from Bardet-Biedl syndrome, chorioretinal atrophy or degeneration, cone or cone-rod dystrophy, congenital stationary night blindness, Leber congenital amaurosis (LCA), macular degeneration (MD), including age-related MD (AMD), ocular-retinal developmental disease, optic atrophy, retinitis pigmentosa, syndromic / systemic diseases with retinopathy, Usher syndrome, or other retinopathy, including diabetic retinopathy.
72. The method of claim 71, wherein the retinal disease is age-related macular degeneration (AMD) or retinitis pigmentosa (RP).
73. A method of delivering a heterologous nucleic acid to a retinal cell comprising contacting the retinal cell with a plurality of the rAAV particles of any one of claims 33 to 61 or the pharmaceutical composition of any one of claims 62 to 64.
